Yi-Feng Tao
Overview
Explore the profile of Yi-Feng Tao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang X, Lu L, Zhu W, Tao Y, Shen C, Chen J, et al.
Hepatobiliary Pancreat Dis Int
. 2024 Nov;
PMID: 39492049
Hepatectomy is still the major curative treatment for patients with liver malignancies. However, it is still a big challenge to remove the tumors in the central posterior area, especially if...
2.
Lu L, Zhu W, Shen C, Tao Y, Wang Z, Chen J, et al.
Hepatobiliary Surg Nutr
. 2024 Aug;
13(4):575-585.
PMID: 39175714
Background: The judgment of the division point of the bile duct has always been one of the difficulties of laparoscopic left lateral sectionectomy (LLLS). The purpose of this study was...
3.
Yang X, Lu L, Zhu W, Tao Y, Shen C, Chen J, et al.
Hepatobiliary Pancreat Dis Int
. 2024 Apr;
23(2):117-122.
PMID: 38619051
Hepatectomy is still the major curative treatment for patients with liver malignancies. However, it is still a big challenge to remove the tumors in the central posterior area, especially if...
4.
Cai X, Li R, Li J, Tao Y, Zhang Q, Shen C, et al.
Front Pharmacol
. 2022 Nov;
13:1031969.
PMID: 36438793
Tacrolimus, a calcineurin inhibitor widely used as a potent immunosuppressant to prevent graft rejection, exhibits nonlinear kinetics in patients with kidney transplantation and nephrotic syndrome. However, whether nonlinear drug metabolism...
5.
Li J, Tao Y, Shen C, Li R, Wang Z, Xing H, et al.
Front Oncol
. 2022 Aug;
12:939948.
PMID: 35992857
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and has a high recurrence rate. Accurate prediction of recurrence risk is urgently required for tailoring personalized treatment...
6.
Pei J, Shen C, Li R, Tao Y, Lu L, Wang Z
Hepatobiliary Pancreat Dis Int
. 2022 Jun;
22(1):92-95.
PMID: 35752597
No abstract available.
7.
Li J, Chen T, Xing H, Li R, Shen C, Zhang Q, et al.
Hepatobiliary Pancreat Dis Int
. 2022 May;
22(3):245-252.
PMID: 35534342
Background: Liver transplantation (LT) is the "cure" therapy for patients with hepatocellular carcinoma (HCC). However, some patients encounter HCC recurrence after LT. Unfortunately, there is no effective methods to identify...
8.
Ying Y, Li R, Ai J, Zhu Y, Zhou X, Qian Y, et al.
Hepatobiliary Pancreat Dis Int
. 2020 Jun;
19(4):358-364.
PMID: 32571745
Background: Infections still represent the main factors influencing morbidity and mortality following liver transplantation. This study aimed to evaluate the incidence and risk factors for infection and survival after liver...
9.
Lu L, Wang Z, Zhu W, Shen C, Tao Y, Ma Z, et al.
Liver Transpl
. 2020 May;
27(1):88-95.
PMID: 32394500
We assess the safety and feasibility of the left hepatic vein preferential approach (LHVPA) based on left hepatic vein (LHV) anatomy for living donor laparoscopic left lateral sectionectomy (LLLS). Data...
10.
Li L, Dong Y, Li R, Tao Y, Shen C, Wang Z
Hepatobiliary Pancreat Dis Int
. 2020 Apr;
19(3):299-302.
PMID: 32327382
No abstract available.